INTRODUCTION
Transfer RNA (tRNA) is one of the most abundant RNA species in the cell ( 1 , 2 ). It functions as an adaptor during the translation of the genetic code at the ribosome. tRNAs exhibit a cloverleaf secondary structure with several conserved domains, including amino acid accepting stem, D-stem and loop, anticodon stem and loop, variable stem or loop and TψC stem and loop.
After transcription by RNA polymerase, tRNA precursors usually undergo posttranscriptional processing, including numerous base or sugar modifications, by various tRNA modifying enzymes ( 2 , 3 ). In fact, tRNAs harbor the most extensive posttranscriptional modification among all cellular RNA species ( 1 ). Specifically, bases in the anticodon loop are the most heavily modified. These modifications play various critical roles in maintaining tRNA structure and stability, limiting or expanding codon-anticodon base pair capacity, restricting the occurrence of frameshifting and promoting tRNA aminoacylation ( 2–4 ).
3-Methylcytidine modification at position 32 (m 3 C32) is present only in eukaryotic cytoplasmic tRNA Thr , tRNA Ser , tRNA Arg (only in mammals) and mitochondrial tRNA Thr and tRNA Ser species ( 5–9 ). The biological function of tRNA m 3 C32 modification in mRNA translation has not been fully established. Considering its location in the anticodon loop, we suggest that it likely participates in regulating loop conformation, codon-anticodon base pairing and/or the biogenesis of tRNA-derived small regulatory RNAs. Loss of cytoplasmic tRNA Ser m 3 C formation was found to influence pluripotency and cancer cell growth ( 10 ).
With respect to the biogenesis of tRNA m 3 C32 in budding yeast, Trm140 is responsible for m 3 C32 modification of both tRNA Thr and tRNA Ser ( 5 , 6 ); however, two enzymes, Trm140 and Trm141, catalyze tRNA Thr and tRNA Ser m 3 C32 modification, respectively, in fission yeast ( 11 ). The rationale for the evolution of the additional gene (Trm141) in fission yeast is unclear. In vivo genetic data have shown that N 6 -threonylcarbamoyladenosine (t 6 A) or N 6 -isopentenyladenosine (i 6 A) modification at position 37 (t 6 A37 or i 6 A37) of yeast tRNA Thr or tRNA Ser functions as a positive determinant in catalyzing m 3 C32 biogenesis by Trm140 and Trm141 ( 11 , 12 ). In mice, Mettl2 has been identified as the m 3 C32 methyltransferase for tRNA Thr and tRNA Arg ; Mettl6 has been identified as the methyltransferase for tRNA Ser , based on the observation that m 3 C32 formation on these specific tRNAs was impaired after deleting the corresponding genes. Interestingly, it has been shown that mRNA also undergoes m 3 C modification, which is mediated by Mettl8. Moreover, Mettl8 knockout has little effect on the m 3 C32 abundance of tRNAs, leading to the hypothesis that Mettl8 is not a tRNA but rather a mRNA m 3 C methyltransferase ( 13 ). A recent study reported that METTL8 is a potential regulator of R-loop stability in the ribosomal RNA (rRNA) gene locus ( 14 ). Indeed, another recent study reported that m 3 C abundance in mRNAs is lower than that in tRNAs ( 15 ). In human cells, two Mettl2 homologs, METTL2A and METTL2B, have further evolved, with amino acid differences at only six positions, for unclear reasons ( 16 ). Recently, we purified human METTL2A, METTL2B and METTL6 and established the m 3 C32 modification activities of all these enzymes. We found that t 6 A37 in human cytoplasmic tRNA Thr is a critical determinant of m 3 C32 biogenesis by METTL2A/2B; however, t 6 A37 in human cytoplasmic tRNA Ser (GCU) plays little role in modification by METTL6, in assistance with cytoplasmic seryl-tRNA synthetase (SerRS, encoded by SARS1 ) ( 16 ). Very recently, we further determined the crystal structure of METTL6, defining its active site and substrate binding patterns ( 17 ).
Among the 22 h uman m itochondrial tRNAs ( hm tRNAs), only tRNA Thr (hmtRNA Thr ) and tRNA Ser (UCN) (hmtRNA Ser (UCN)) contain m 3 C32 modification ( 9 ). Meanwhile, hmtRNA Thr and hmtRNA Ser (UCN) harbor a t 6 A37 modification, catalyzed by YRDC and OSGEPL1 ( 18 , 19 ), and a i 6 A37 modification mediated by TRIT1 ( 20 , 21 ), respectively. Of the four known m 3 C modifying enzymes (METTL2A, METTL2B, METTL6 and METTL8), METTL2A/2B and METTL6 are distributed in the cytoplasm but not the mitochondria, suggesting that they do not function as mitochondrial m 3 C32-modifying enzymes ( 16 ). Therefore, the enzyme responsible for mammalian tRNA Thr and tRNA Ser (UCN) m 3 C32 biogenesis has long been a mystery. However, a recent mitochondrial proteome screening found that METTL8 is located in the mitochondrial fraction, eliciting the question of whether METTL8 is the missing mitochondrial tRNA m 3 C32 methyltransferase ( 22 ). Indeed, METTL8 has very recently been proven to be the mitochondrial tRNA m 3 C32 methyltransferase ( 23 ).
Despite being revealed as a multifunctional protein, however, the localization of METTL8 in mitochondria as a tRNA m 3 C32 modifying enzyme ( 23 ) seemingly contradicts the findings that Mettl8 potentially mediates mRNA m 3 C formation in mouse cells ( 13 ) and regulates R-loop biogenesis and stability in human cells ( 14 ), which require the presence of METTL8 in the cytoplasm and/or nucleolar fraction. To more clearly understand these seemingly inconsistent findings about the multiple roles of METTL8, we initially analyzed all potential mRNA and protein isoforms in detail and identified several protein variants that were generated via alternative splicing of METTL8 mRNA. The longest variant, METTL8-Iso1, harbors an N-terminal mitochondrial targeting sequence (MTS), which facilitates its import into mitochondria. We further precisely established the mature form of METTL8-Iso1 and reconstituted both hmtRNA Thr and hmtRNA Ser (UCN) m 3 C32 modification activity of METTL8-Iso1. Our results showed that i 6 A37 of hmtRNA Ser (UCN) but not t 6 A37 of hmtRNA Thr constituted the key determinant in modification and further established a tRNA recognition mechanism by METTL8-Iso1 using hmtRNA Thr transcript. METTL8-Iso1 interacted with SARS2 (mitochondrial SerRS) but exhibited SARS2-independent activity.
In summary, our results significantly deepen our understanding of METTL8 gene expression and the mitochondrial tRNA m 3 C32 modification mechanism of METTL8-Iso1. In combination with our recent elucidation of the cytoplasmic tRNA m 3 C32 biogenesis mechanism involving METTL2A and METTL6 ( 16 ), these results collectively provide valuable insights into both the similarity and divergence between cytoplasmic and mitochondrial tRNA m 3 C32 modifications.
MATERIALS AND METHODS
Materials
S-Adenosylmethionine (SAM) was obtained from New England Biolabs (Ipswich, MA, USA). Protease inhibitor cocktail, horseradish peroxidase (HRP)-conjugated secondary antibodies, protein standards for gel filtration chromatography, anti-FLAG (F7425), anti-Myc (M4439) and anti-GAPDH (G8795) antibodies were purchased from Sigma (St. Louis, MO, USA). Anti-GFP (4B10) antibody was obtained from Cell Signaling Technology (Boston, MA, USA). Dynabeads Protein G, MitoTracker, RNase I (RNase) and restriction enzymes were obtained from Thermo Scientific (Waltham, MA, USA). Lipofectamine 8000 transfection reagent and 4’,6-diamidino-2-phenylindole (DAPI) were obtained from Beyotime Biotech (Shanghai, China). Polyvinylidene fluoride (PVDF) membranes were purchased from Merck (Darmstadt, Germany). Primers were synthesized by Biosune (Shanghai, China), and DNA sequencing was performed by Tsingke (Shanghai, China). PrimeScript RT Master Mix was obtained from Takara Bio (Kusatsu, Japan). Dimethylallyl diphosphate (DMAPP) was obtained from APExBIO Technology (Houston, TX, USA). The BCA Protein Assay Kit was obtained from TIANGEN Biotech (Beijing, China). [ 3 H] SAM and [ 3 H] DMAPP were obtained from Perkin Elmer, Inc. (Waltham, MA, USA). t 6 A (sc-286478) and m 3 C (HY-111645) standard samples for mass spectrometry were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and MedChemExpress (Monmouth Junction, NJ, USA), respectively.
Plasmid construction and gene expression
Genes encoding different METTL8 (UniProt No. Q9H825 ) isoforms were amplified from cDNA obtained by reverse transcription of total RNA from human embryonic kidney 293T (HEK293T) cells and inserted between the XhoI and EcoRI sites of pEGFP-N2 with a C-terminal EGFP tag. The initiating Met codon (ATG) of EGFP was mutated to the Ile codon (ATC) to prevent the potential generation of free EGFP. The gene encoding METTL8-Iso1 was also inserted between the NotI and XhoI sites of pCMV-3Tag-3A with C-terminal 3 × FLAG tags. Mature METTL8-Iso1 and METTL8-Iso4 were inserted between the NcoI and XhoI sites of pET28a with a C-terminal His 6 -tag for expression and purification in an E. coli expression system. A plasmid expressing mature SARS2 (Thr 35 -Ser 518 ) was constructed and expressed as described in a previous report ( 19 ). Full-length SARS2 was inserted between the EcoRI and NotI sites of pcDNA3.1 with a C-terminal Myc-tag. The gene encoding Escherichia coli MiaA ( Ec MiaA) (UniProt No. P16384 ) was amplified by PCR from the E. coli genome and inserted between the NcoI and XhoI sites of pET28a with a C-terminal His 6 -tag. The plasmid expressing Saccharomyces cerevisiae Sua5 ( Sc Sua5) (UniProt No. P32579 ) was constructed and expressed as reported previously ( 19 , 24 ). All primers used in gene cloning are listed in Supplementary Table 1 .
For gene expression in E. coli , constructs were transformed into E. coli BL21 (DE3) cells. METTL8-Iso1, METTL8-Iso4 and Ec MiaA gene expression was induced with a final concentration of 200 μM isopropyl β- d -1-thiogalactopyranoside (IPTG), and S. cerevisiae KEOPS ( Sc KEOPS) expression from pJ241- Sc KEOPS ( 25 ) was induced with a final concentration of 500 μM IPTG when the initial cell culture reached an absorbance at 600 nm ( A 600 ) of 0.6–0.8. Transformants were cultured overnight at 18°C. Proteins were purified by Ni 2+ -NTA Superflow resin according to the manufacturer's protocol. The purified METTL8 proteins were concentrated and further purified on a HiTrap Q FF column and dialyzed against storage buffer (50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 2 mM DDT). The purified Ec MiaA proteins were concentrated and dialyzed against storage buffer (50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 2 mM DDT). The purified Sc KEOPS was concentrated and further purified via ion exchange chromatography (Mono Q column) and then dialyzed against storage buffer (25 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM β-ME). All purified proteins were mixed with an equal volume of glycerol and then stored at –20°C. The protein concentrations were determined by using a BCA Protein Assay Kit according to the manufacturer's instructions.
tRNA gene cloning and transcription
Plasmids for in vitro transcription of hmtRNA Thr , hmtRNA Lys -Ki and hmtRNA Trp were constructed as previously reported ( 19 , 24 , 26 ). hmtRNA Ser (UCN), hmtRNA Tyr , hmtRNA Leu (UUR), hmtRNA Phe and hmtRNA Met were engineered into the pTrc99b plasmid. A hammerhead ribozyme was added between the T7 promoter and hmtRNA Phe gene to improve transcription efficiency ( 27 ). Note that a mutant of hmtRNA Lys , hmtRNA Lys -Ki (U50:A64) (with A50:U64 in wild-type hmtRNA Lys replaced with U50:A64), which has been shown to substitute well for wild-type hmtRNA Lys ( 28 ), was transcribed and used in this study to avoid misfolding. tRNA gene mutagenesis was performed according to the protocol provided with the KOD-plus mutagenesis kit. All tRNAs were obtained by in vitro tRNA transcription, which was performed as previously described ( 19 , 29 ). The primers used for template preparation are listed in Supplementary Table 1 .
Determination of in vitro m 3 C and i 6 A modification
The m 3 C modification reaction was performed at 37 °C in a 40 μl reaction mixture containing 50 mM Tris–HCl (pH 7.5), 20 mM KCl, 10 mM MgCl 2 , 1 mM DTT, 1 mM spermidine, 100 μM [ 3 H] SAM, 5 μM hmtRNAs (or variants) and 1 μM mature METTL8-Iso1 (or METTL8-Iso1 and SARS2 in different molar ratios). The i 6 A modification reaction was performed at 37 °C in a 10 μl reaction mixture containing 50 mM Tris-HCl (pH 7.5), 3.5 mM MgCl 2 , 1 mg/ml BSA, 5 mM β-ME, 30 μM [ 3 H] DMAPP, 5–15 μM hmtRNAs (or variants) and 1 μM Ec MiaA. Aliquots of the reaction solution were added to filter pads at various time points (for m 3 C modification) or at 15 min (for i 6 A modification) and quenched with cold 5% TCA. The pads were washed three times for 15 min each with cold 5% TCA and then three times for 10 min each with 100% ethanol. Finally, the pads were dried under a heat lamp, and the radioactivity of the precipitates was quantified using a scintillation counter (Beckman Coulter, Atlanta, GA, USA).
Reverse transcription and identification of METTL8 mRNAs
Total RNA was extracted from HEK293T cells using TRIzol reagent. cDNAs were reverse-transcribed using PrimeScript RT Master Mix according to the manufacturer's protocol. After cDNA synthesis, PCR was performed with different primers using 2 × Taq Master Mix according to the manufacturer's protocol. PCR products were separated via agarose gel electrophoresis, the relevant bands were excised, and the DNA was extracted with a HiPure Gel Pure Micro Kit and sequenced by Tsingke. The DNA sequencing results were then compared with various exon sequences to define alternative splicing patterns. The locations of the primers and exons are described in the Results section, and the primer sequences are listed in Supplementary Table 1 .
Cell culture, transfection and coimmunoprecipitation (Co-IP)
HEK293T cells were cultured in DMEM supplemented with 10% FBS in a 37°C incubator with 5% CO 2 at a confluence of 70% before transfection using Lipofectamine 8000 transfection reagent according to the manufacturer's protocol. For co-IP, at 24 h after transfection, cells were harvested, washed with ice-cold PBS three times, and lysed for 30 min at 4 °C with rotation in 1 ml of ice-cold lysis buffer (50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA, 1% NP-40 and 0.25% sodium deoxycholate) supplemented with a protease inhibitor cocktail. The supernatant was collected by centrifugation at 12,000 g for 20 min. Whole cell lysates were supplemented with anti-FLAG antibodies, incubated overnight with rotation, and then treated with Dynabeads protein G for an additional 4 h. The recovered immune complexes were washed three times with ice-cold PBS containing 0.05% Tween-20 (PBST). Protein was eluted from the beads in 2 × protein loading buffer comprising 100 mM Tris–HCl (pH 7.0), 4% SDS, 0.2% bromophenol blue, 20% glycerol and 200 mM DTT.
Fluorescence assays
After cell culture and transfection, the cells were incubated with MitoTracker at a 1:20,000 dilution for 30 min in a 37 °C incubator. After washing 3 times, the cells were fixed in 4% paraformaldehyde for 30 min, washed with PBS 3 times, and then permeabilized in 0.2% Triton X-100 and 1% BSA for 5 min on ice. After washing with PBS 3 times again, the fixed and permeabilized cells were blocked in PBS containing 4% BSA, washed with PBS 3 times, and then immunolabeled with the nuclear counterstain DAPI in PBS at a 1:1000 dilution for 5 min at RT. Fluorescent images were taken using a Leica TCS SP8 STED confocal microscope and analyzed.
Preparation of t 6 A- and i 6 A-modified tRNAs
For preparation of t 6 A-modified hmtRNA Thr , the t 6 A modification reaction was performed at 37 °C for 1 h in a 200 μl reaction mixture containing 50 mM Tris–HCl (pH 8.0), 200 mM NaCl, 15 mM MgCl 2 , 4 mM ATP, 5 mM DTT, 5 mM MnCl 2 , 50 mM NaHCO 3 , 1 mM L-Thr, 10 μM hmtRNA Thr and 5 μM yeast Sua5 ( 30 ) and KEOPS complex ( 31 ). For the preparation of i 6 A-modified hmtRNAs, an i 6 A modification reaction was performed at 37°C for 30 min in a 200 μl reaction mixture containing 50 mM Tris–HCl (pH 7.5), 3.5 mM MgCl 2 , 1 mg/ml BSA, 5 mM β-ME, 0.5 mM DMAPP, 20 μM hmtRNAs and 5 μM Ec MiaA ( 32 ). The t 6 A- or i 6 A-modified tRNA was purified by phenol/chloroform and precipitated by EtOH with NaAc overnight at –20°C. The modified tRNA concentration was determined by denaturing urea–PAGE based on linear curves from tRNA transcript samples with known concentrations.
Ultra-performance liquid chromatography–mass spectrometry/mass spectrometry (UPLC–MS/MS) analysis
For UPLC–MS/MS, 500 ng of unmodified or m 3 C-, t 6 A- or i 6 A-modified tRNA sample was digested with 1 U of nuclease P1 and 0.5 U of benzonase nuclease in a 20 μl solution including the nuclease P1 buffer supplied with the kit and 20 mM NH 4 OAc (pH 5.2) at 37°C for 6 h. Then, 0.5 U of calf alkaline phosphatase (CAP) and 0.5 U of bacterial alkaline phosphatase (BAP) with CAP buffer were added to the reaction solution. After complete hydrolysis at 37°C overnight and filtration, 1 μl of product was subjected to UPLC–MS/MS. m 3 C and t 6 A were detected with Poroshell 120 PFP column (Agilent) and i 6 A was detected with Hypersil GOLD aQ column (Thermo Scientific).
Western blotting
After co-IP or protein purification, protein samples were separated on a 10% separating gel via SDS–PAGE. Western blotting was performed as described in a previous report ( 33 ).
Gel filtration analyses of mature METTL8-Iso1 and METTL8-Iso4
Purified mature METTL8-Iso1 and METTL8-Iso4 were analyzed by gel filtration chromatography on a Superdex 200 column using running solution (50 mM Tris–HCl (pH 8.0), 150 mM NaCl) at a rate of 0.5 ml/min. Protein standards were also loaded and eluted under the same conditions. A linear calibration curve was obtained by plotting the logarithms of the known molecular masses of the standards versus their elution times.
Insect cell culture, transfection, expression and determination of the N-terminal sequence of mature METTL8-Iso1
Sf9 and High Five cells were cultured in Sf-900 II SFM medium at 27°C. The pFastBac2-METTL8-Iso1 precursor was constructed with a C-terminal His 6 tag for gene expression in insect cells by inserting the gene encoding the METTL8-Iso1 precursor between the BamHI and XhoI sites of pFastbac2. Recombinant baculoviruses were generated by transfecting the bacmid into Sf9 cells using Cellfectin II reagent according to the manufacturer's protocol. P1 virus stock was harvested after 6–7 days at 27 °C and used to infect Sf9 cells, which were then incubated for 5–6 days at 27°C to produce a higher-titer P2 virus stock. The same procedure was used to produce P3 virus stock, which was then stored at 4°C with protection from light. Gene expression was performed by infecting High Five cells in Sf-900 II SFM medium with P3 virus stock at a 1:200 ratio. Cells were harvested by centrifugation (500 g , 5 min) 66 h after infection, washed in PBS and stored at –80°C. The High Five cells were disrupted by sonication on ice, and the whole cell lysate was applied to Ni-NTA Superflow resin for mature METTL8-Iso1 purification according to the manufacturer's protocol. The eluted proteins were separated on a 10% separating gel via SDS–PAGE and transferred to PVDF membranes in CAPS transfer buffer (10 mM CAPS, 10% methanol), stained with Ponceau red for 25 min and washed with ultrapure water. The washing steps were repeated several times until the band of interest was clearly visible. The band was excised and sent to BiotechPack Scientific (Beijing, China) for identification of the N-terminal sequence through the Edman degradation method.
RESULTS
METTL8 encodes several isoforms via mRNA alternative splicing
Seven protein isoforms of the human METTL8 gene have been deposited in the NCBI database ( Supplementary Figure 1 ). Primary sequence alignment of these isoforms, together with other m 3 C32 methyltransferases, including yeast Trm140 and Trm141 and mammalian METTL2A, METTL2B and METTL6, showed that isoforms 5–7 are truncated (Figure 1A ). Comparison with our recently resolved crystal structure of METTL6 (PDB No. 7EZG) ( 17 ) reveals that isoforms 5–7 of METTL8 lack a complete SAM- and tRNA-binding domain. An absolutely conserved residue in METTL6, Thr 217 , has been shown to be critical for m 3 C32 methylation, likely due to impaired tRNA binding ( 17 ). Notably, its counterpart was absent in isoforms 5–7 but present in isoforms 1–4 of METTL8 (Thr 337 in isoform 1) ( Supplementary Figure 1 ). Therefore, isoforms 5–7 are unlikely to be m 3 C32-modifying enzymes. Based on these observations, we focus mainly on the presence or absence of isoforms 1–4 in this work. Notably, isoforms 3 and 4 (designated METTL8-Iso3 and -Iso4 hereafter) differ only in the presence of five additional amino acids ( 1 MPRDH 5 ) in the N-terminus of METTL8-Iso3. Compared with METTL8-Iso3 or -Iso4, isoforms 1 and 2 (METTL8-Iso1 and -Iso2) contain longer extensions of the N-terminus (Figure 1A , Supplementary Figure 1 ).
METTL8 contains 12 exons (sequence of each exon is shown in Supplementary Table 2 ). Retrieved mRNA sequences encoding these protein isoforms in the NCBI database showed that METTL8-Iso1 was potentially encoded by four mRNA sequences (mRNAs 1v1-4) produced by alternative splicing (Figure 1B ). mRNA sequences (mRNAs 2–7), sequentially encoding METTL8-Iso2 to METTL8-Iso7, were also generated by mRNA alternative splicing (Figure 1B ). To distinguish and confirm the sequences of these mRNAs, we designed three forward primers (F1 complementary to exon 1; F2 to exon 2 and F3 to exon 4) (Figure 1B ). Using cDNA from HEK293T cells, in combination with a universal reverse primer (R1 complementary to exon 6), we amplified several fragments. In detail, using F1 and R1, a weak fragment was obtained, which was then sequenced and found to have 341 bp, derived from mRNA 3 and/or mRNA 6, encoding METTL8-Iso3 and/or METTL8-Iso6, respectively (Figure 1C ). Two obvious fragments amplified with F2 and R1 were sequenced and found to be 505 and 350 bp, clearly showing the existence of mRNA 1v2 (encoding METTL8-Iso1) and mRNA 4 (encoding METTL8-Iso4). In addition, two weak but detectable fragments of 474 and 629 bp were also obtained and sequenced. The former was definitely derived from mRNA 7, while the latter fragment indicated the existence of mRNA 5 (encoding METTL8-Iso5) and/or mRNA 1v3 (still encoding METTL8-Iso1) (Figure 1C ). A 411 bp fragment was obtained with F3 and R1 and sequenced, indicating that the cDNA template was qualified, but it could not be assigned to an mRNA isoform (Figure 1C ). The presence of mRNAs 5–7 was further confirmed by amplification with forward primer F4 (complementary to exon 9) and reverse primer R2 (complementary to exon 11), which produced a 449 bp fragment showing that exon 10 was indeed skipped, in addition to a 556 bp fragment that included exon 10 (Figure 1D ). Notably, amplification of DNA products of 505, 350 and 474 bp with F2 and R1 primers definitely showed the presence of mRNA 1v2, mRNA 4 and mRNA 7 in human cells.
In summary, the above results showed a complex mRNA alternative splicing landscape of the METTL8 gene in human HEK293T cells. In detail, at least two distinct mRNAs (including mRNAs 1v2 and 4) encode two full-length protein isoforms (METTL8-Iso1 and METTL8-Iso4). In addition, at least mRNA 7 encoded a truncated protein lacking a complete SAM- and tRNA-binding domain and was not further investigated in this study.
Cellular localization of METTL8 protein isoforms
As described above, METTL8-Iso3 and METTL8-Iso4 are nearly the same, with a difference of only five additional amino acids ( 1 MPRDH 5 ) in the N-terminus of METTL8-Iso3. Compared with METTL8-Iso4, METTL8-Iso1 has a longer N-terminal extension (Met 1 -His 50 , NTD50). MitoProt software ( 34 ) predicted no mitochondrial distribution of either METTL8-Iso3 or METTL8-Iso4; however, METTL8-Iso1 exhibited a higher probability (with a score of 0.8052) of import into mitochondria, suggesting that it is a mitochondrial protein, in accordance with a recent proteome analysis reporting mitochondrial localization of METTL8 in human mitochondria ( 22 ).
The open reading frames (ORFs) encoding METTL8-Iso1, -Iso3 and -Iso4 could all be readily amplified from HEK293T cDNA. Three ORFs were individually cloned into pEGFP-N2 to express C-terminal EGFP-fusion proteins. Fluorescence analysis showed that the main fractions of both METTL8-Iso3 and METTL8-Iso4 were located in the nucleolus, which was confirmed by their colocalization with fibrillarin (FBL), a key small nucleolar protein involved in pre-rRNA processing ( Supplementary Figure 2A ). However, METTL8-Iso1 was obviously distributed in the mitochondrial fraction, as stained by MitoTracker (Figure 2 ). The mitochondrial localization of METTL8-Iso1 was also confirmed by immunostaining of a C-terminal FLAG-tagged METTL8-Iso1 (METTL8-Iso1-FLAG) using anti-FLAG antibodies ( Supplementary Figure 2B ). Furthermore, the N-terminal extension of METTL8-Iso1, NTD50, was cloned upstream of EGFP. Consistently, the overexpressed NTD50-EGFP was exclusively targeted to mitochondria, suggesting a high efficiency of NTD50 in promoting the import of a foreign protein into the mitochondria (Figure 2 ).
In summary, the above data clearly showed that two METTL8 isoforms (METTL8-Iso3 and METTL8-Iso4) are mainly located in the nucleolar fraction, while METTL8-Iso1 is present in the mitochondria, indicating that METTL8-Iso1 is an m 3 C methyltransferase in this organelle.
Purification of the mitochondrial form of METTL8-Iso1
To reconstitute potential mitochondrial tRNA m 3 C32 modification, it was necessary to purify METTL8-Iso1. The MitoProt database predicted that the cleavage site of METTL8-Iso1 after import into the mitochondrial matrix was between Phe 43 and Glu 44 . However, we observed frequent inaccuracy in locating precise cleavage sites during studies of human mitochondrial aminoacyl-tRNA synthetases (such as LARS2, TARS2 and AARS2) ( 29 , 35–37 ) and tRNA modifying enzymes (such as GTPBP3) ( 38 ). Instead, we found that N-terminal protein sequencing by automatic Edman degradation after gene expression and purification of the mitochondrial proteins in a Bac-to-Bac baculovirus expression system is an excellent method for establishing the exact MTS ( 35 , 38 ). To this end, the gene encoding the METTL8-Iso1 precursor was expressed with a C-terminal His 6 tag in the baculovirus expression system and subsequently purified by Ni-NTA affinity chromatography ( Supplementary Figure 3 ). The N-terminus of purified METTL8-Iso1 was determined to be SGYHPV, clearly establishing that Met 1 -Gln 22 is the MTS of METTL8-Iso1, in contrast to the predicted peptide (Met 1 -Phe 43 ) ( Supplementary Figure 1 ). To validate the mitochondrial targeting capacity of Met 1 -Gln 22 , a gene encoding mature METTL8-Iso1 (with Met 1 -Gln 22 deleted) and a C-terminal EGFP fusion was overexpressed in HEK293T cells. Consistently, the EGFP-fused Met 1 -Gln 22 -truncated METTL8-Iso1 was distributed in both the nucleus and cytoplasm but no longer in the mitochondria (Figure 2 ), showing loss of mitochondrial localization of Met 1 -Gln 22 -truncated METTL8-Iso1 in the absence of the MTS.
Then, the gene encoding mature METTL8-Iso1 (with N-terminal Met 1 -Gln 22 deleted) was expressed in E. coli and purified (Figure 3A ). Both METTL2A and METTL6 are shown to be monomers in solution. To understand the quaternary structure of mature METTL8-Iso1, the protein was subjected to gel filtration analysis with Superdex S200 (Figure 3B ). The results unexpectedly showed that METTL8-Iso1 eluted in a single peak with an elution volume between those of apoferritin (443 kDa) and yeast alcohol dehydrogenase (150 kDa). Based on the elution volume of the four protein standards, the calculated molecular mass was 346.6 kDa (Figure 3C ). The theoretical molecular mass of purified METTL8-Iso1 with a C-terminal His 6 tag is 45.3 kDa; these results suggested that mature METTL8-Iso1 exists as a polymer (likely octamer) in solution. We further purified METTL8-Iso4 from E. coli (Figure 3A ), and the same analysis revealed that the molecular mass of purified METTL8-Iso4 was 60.47 kDa (Figure 3C ), suggesting that METTL8-Iso4 (theoretical molecular mass 42.1 kDa) is possibly a monomer in solution. The clear difference between the quaternary structures of mature METTL8-Iso1 and METTL8-Iso4 is unanticipated considering that the former is only 28 aa longer than the latter at the N-terminus ( Supplementary Figure 1 ). The reason for this difference is unclear and needs to be studied further.
To further confirm that METTL8-Iso1 forms a polymer in vivo , genes encoding METTL8-Iso1-FLAG and METTL8-Iso1-EGFP were coexpressed in HEK293T cells. Coimmunoprecipitation (co-IP) analysis using anti-FLAG antibodies showed that METTL8-Iso1-EGFP indeed coprecipitated with METTL8-Iso1-FLAG (Figure 3D ), suggesting that METTL8-Iso1 forms polymers in vivo .
m 3 C32 biogenesis by METTL8-Iso1 is not reliant on t 6 A37 modification
After obtaining purified METTL8-Iso1, we subsequently explored whether METTL8-Iso1 is able to modify the hmtRNA Thr transcript or requires a preformed t 6 A moiety as a determinant, as revealed by the modification of cytoplasmic tRNA Thr by METTL2A ( 16 ). Indeed, METTL8-Iso1 obviously generated m 3 C modification in the hmtRNA Thr transcript (Figure 4A ). To understand whether position 32 was modified, we mutated C32 to three other nucleotides, generating the hmtRNA Thr -C32A, -C32U and -C32G mutants (Figure 4B ). The three mutants were unable to be modified by METTL8-Iso1, suggesting that position 32 was modified. The modified hmtRNA Thr transcript was further hydrolyzed to mononucleosides and analyzed by UPLC–MS/MS, confirming the formation of m 3 C modification (Figure 4C ). These data showed that METTL8-Iso1 indeed modified the hmtRNA Thr transcript with m 3 C at position 32.
We further prepared t 6 A37-modified hmtRNA Thr (t 6 A-hmtRNA Thr ) using yeast Sua5 and KEOPS complex ( 39 ), which was confirmed by UPLC–MS/MS analysis after digestion of t 6 A-hmtRNA Thr into mononucleosides ( Supplementary Figure 4 ). We found that METTL8-Iso1 introduced comparable amounts of the m 3 C moiety into t 6 A-hmtRNA Thr and the hmtRNA Thr transcript (Figure 4A ). These data clearly showed that t 6 A formation at position 37 has little stimulatory effect on m 3 C32 biogenesis by METTL8-Iso1 in vitro , which is in sharp contrast to its role in modification by METTL2A ( 16 ).
Mechanism of hmtRNA Thr recognition by METTL8-Iso1
After establishing that the hmtRNA Thr transcript is a qualified METTL8-Iso1 substrate, we further studied how it is selected among the mitochondrial tRNAs. Our previous studies on the METTL8 homologs METTL2A and METTL6 revealed that the anticodon loop is a key element for m 3 C32 formation by both enzymes ( 16 ). Based on these results, we targeted the anticodon loop of hmtRNA Thr . We mutated each nucleotide in the anticodon loop (U33, U34, G35, U36, A37 and A38) into three other nucleotides (Figure 5A ). hmtRNA Thr -U33G was not modified by METTL8-Iso1, while hmtRNA Thr -U33A and hmtRNA Thr -U33C were modified with comparable efficiency to wild-type hmtRNA Thr (Figure 5B ). For position 34, hmtRNA Thr -U34A and hmtRNA Thr -U34G were not modified, while the modification efficiency of hmtRNA Thr -U34C was even higher than that of wild-type hmtRNA Thr (Figure 5C ). Strikingly, none of the G35 mutants were modified. Position 35 has no interaction with other nucleotides in tRNAs. Mutation at this residue has little possibility to influence tRNA folding and structure. Therefore, no modification of all G35 mutants clearly revealed that G35 functions as a positive determinant of m 3 C32 biogenesis by METTL8-Iso1 (Figure 5D ). For position 36, only hmtRNA Thr -U36A was obviously modified, but with a reduced (approximately half) efficiency (Figure 5E ). The results from mutants of A37 showed that hmtRNA Thr -A37G was only slightly modified, while hmtRNA Thr -A37U and hmtRNA Thr -A37C displayed higher or comparable modification efficiency than wild-type hmtRNA Thr (Figure 5F ). Finally, hmtRNA Thr -A38G was not modified, while hmtRNA Thr -A38U and hmtRNA Thr -A38C exhibited reduced modification efficiency (Figure 5G ).
Altogether, the observation of a lack of reliance on t 6 A37 enables us to establish a full understanding of the roles of individual nucleotides in the anticodon loop in m 3 C32 biogenesis of mitochondrial tRNA. Our results showed that G35 is a critical determinant, and the sequence requirement of the anticodon loop is determined as follows: C32-(U/A/C)33-(C > U)34-G35-(U > A)36-(U > A = C > G)37-(A > U > C)38.
The newly evolved A29-C41 mismatch fine-tunes the m 3 C32 level of hmtRNA Thr
An evolutionary analysis in our previous study identified that an A29-C41 mismatch was newly evolved in the mitochondrial tRNA Thr of human and gorilla but not those of other mammals, for unknown reasons ( 24 ). Based on the key role of the anticodon stem in m 3 C32 biogenesis by METTL2A, we wondered whether an A29-C41 mismatch in hmtRNA Thr could influence m 3 C32 modification by METTL8-Iso1. We mutated either A29 to G29 or C41 to U41 ( Supplementary Figure 5A ). The resultant hmtRNA Thr -A29G and hmtRNA Thr -C41U have an anticodon stem with full Watson–Crick base pairing (G29–C41 or A29–U41). Tests of modification by METTL8-Iso1 indeed showed that both mutants were modified with a significantly higher efficiency ( Supplementary Figure 5B ).
In agreement with these observations, the disease-causing G30A mutation, leading to disruption of the anticodon stem ( 24 ), abolished m 3 C32 modification ( Supplementary Figure 5C ). Our previous result also showed that in the context of the G30A mutation, an additional C40U mutation is able to restore the tRNA structure, thermal stability and aminoacylation capacity ( 24 ); however, hmtRNA Thr -G30A/C40U was still a poor substrate of METTL8-Iso1 ( Supplementary Figure 5C ). In addition, when we mutated A39 to G39, changing the U31–A39 Watson–Crick base pair to the U31–G39 wobble base pair, hmtRNA Thr -A39G was modified, but with reduced efficiency ( Supplementary Figure 5C ).
Taken together, these results suggest that the anticodon stem plays an important role in determining m 3 C32 biogenesis and that the newly evolved A29-C41 mismatch is able to fine-tune the m 3 C32 levels in hmtRNA Thr .
i 6 A37 is a positive determinant of m 3 C32 biogenesis in hmtRNA Ser (UCN)
After establishing that METTL8-Iso1 is active in catalyzing hmtRNA Thr m 3 C32 formation, we investigated its modification activity toward hmtRNA Ser (UCN). However, the hmtRNA Ser (UCN) transcript was not modified (Figure 6A ), suggesting that it is not a qualified substrate or that METTL8-Iso1 alone is insufficient in mediating hmtRNA Ser (UCN) m 3 C modification in vitro . Considering that t 6 A37 and i 6 A37 are frequently found to be prerequisites for m 3 C32 formation in yeast and human cytoplasmic tRNAs ( 11 , 12 , 16 ), we reasoned that METTL8-Iso1 probably requires i 6 A37 of hmtRNA Ser (UCN). We purified Ec MiaA and found that it efficiently introduced an i 6 A moiety to hmtRNA Ser (UCN) (Figure 6B ), consistent with a previous report that only A36-A37-A38 is required by Ec MiaA ( 32 ). The i 6 A moiety of the Ec MiaA-prepared hmtRNA Ser (UCN) was further confirmed by UPLC–MS/MS analysis (Figure 6C ). We found that prepared i 6 A-hmtRNA Ser (UCN) was indeed a substrate of METTL8-Iso1 (Figure 6A ). Therefore, these data clearly revealed that i 6 A37 functions as a positive determinant for m 3 C32 modification by METTL8-Iso1.
SARS2 interacts with METTL8-Iso1 directly but only slightly stimulates its modification activity
Modification of cytoplasmic tRNA Ser (GCU) by METTL6 critically relies on the presence of SARS1 due to augmented tRNA binding of the long variable arm of tRNA Ser (GCU) by SARS1. However, METTL6 does not bind SARS1 directly ( 16 ). Mitochondrial tRNA Ser (UCN) is unique in that it lacks the class II tRNA-defining long variable arm. This structural deviation prompted us to ask whether METTL8-Iso1 is able to interact with SARS2. To this end, both METTL8-Iso1-FLAG and a C-terminal Myc-tagged SARS2 (SARS2-Myc) were coexpressed in HEK293T cells. Co-IP purification showed that SARS2-Myc indeed coprecipitated with METTL8-Iso1-FLAG. Furthermore, the addition of RNase to the whole cell lysate prior to co-IP had no effect on the copurification of both enzymes (Figure 7A ). These results revealed that METTL8-Iso1 interacted with SARS2 in an RNA-independent mode, in contrast to the METTL2A-SARS1 interaction, which requires tRNA as a scaffold ( 13 , 16 ).
To understand whether the presence of SARS2 was able to stimulate the activity of METTL8-Iso1, mature SARS2 was purified ( Supplementary Figure 6 ). We incubated increasing concentrations of SARS2 relative to METTL8-Iso1, and m 3 C32 modification activity assays showed that SARS2 only slightly elevated the modification of i 6 A-hmtRNA Ser (UCN) (Figure 7B ). The highest activity of METTL8-Iso1 was observed at a relative molar ratio of 1:2 (METTL8-Iso1 to SARS2), and further elevation of the SARS2 concentration (molar ratio of METTL8-Iso1 to SARS2 of 1:5) provided little stimulatory activity. Again, the hmtRNA Ser (UCN) transcript was not a substrate of SARS2 and METTL8-Iso1 (Figure 7C ), suggesting that the interaction of METTL8-Iso1 with SARS2 did not abrogate the prerequisite for i 6 A37 modification.
Altogether, these results showed that SARS2 interacted with METTL8-Iso1 directly but only slightly stimulated its modification activity.
G35 is important but no longer a determinant in hmtRNA Ser (UCN)
Considering the divergence in the requirement of t 6 A37 or i 6 A37 between hmtRNA Thr and hmtRNA Ser (UCN) by METTL8-Iso1, we wanted to know whether there is difference in the role of nucleotides in the anticodon loop of hmtRNA Ser (UCN) in m 3 C32 biogenesis. Due to the preparation of the i 6 A37 modification, A36-A37-A38 could not be mutated ( 32 ). Therefore, we constructed six mutants of hmtRNA Ser (UCN), including hmtRNA Ser (UCN)-U33A, -U33G, -U34C, -U34G, -G35U and -G35C (Figure 8A ). Ec MiaA was unable to efficiently introduce i 6 A to hmtRNA Ser (UCN)-U33A and -U33G for unknown reasons; therefore, these two mutants were further excluded from the following assays. hmtRNA Ser (UCN)-U34C, -U34G, -G35U and -G35C exhibited slightly decreased i 6 A37 modification levels (within 2-fold) ( Supplementary Figure 7A ). After obtaining i 6 A-modified tRNA mutants, assays of m 3 C32 modification by mature METTL8-Iso1 showed that hmtRNA Ser (UCN)-U34C and -G35C were obviously modified, albeit with reduced efficiencies, which might be attributable to a small decrease in i 6 A modification levels ( Supplementary Figure 7A ). In sharp contrast, both hmtRNA Ser (UCN)-U34G and -G35U were not modified (Figure 8B ), in spite of their comparable i 6 A modification efficiencies with those of hmtRNA Ser (UCN)-U34C and -G35C ( Supplementary Figure 7A ). Notably, hmtRNAThr-U34C displayed a higher modification efficiency than wild-type hmtRNA Thr , and none of the hmtRNA Thr G35 mutants were modified (Figure 5C and D ). These data collectively revealed divergent recognition of hmtRNA Thr and hmtRNA Ser (UCN) by METTL8-Iso1 and showed that G35 in hmtRNA Ser (UCN), while important, is not a determinant of m 3 C32 modification.
Converting other mitochondrial tRNAs to be substrates of METTL8-Iso1
Based on the requirement for C32-(U/A/C)33-(C > U)34-G35-(U > A)36-(U > A = C > G)37-(A > U > C)38 in the anticodon of hmtRNA Thr for m 3 C32 formation by METTL8-Iso1, we checked the mitochondrial tRNA sequences and found that several tRNAs harbor a similar anticodon loop sequence lacking only the G35 nucleotide, such as hmtRNA Lys , hmtRNA Leu (UUR) and hmtRNA Met (Figure 9A ). Thus, we mutated base 35 of these tRNAs to G35 to produce hmtRNA Lys -Ki-G35, hmtRNA Leu (UUR)-G35 and hmtRNA Met -G35 (Figure 9A ). The wild-type tRNAs and their mutants were subsequently modified by METTL8-Iso1, and the results showed that hmtRNA Met -G35 was modified with an obviously higher efficiency than hmtRNA Thr (Figure 9B ). In parallel, hmtRNA Lys -Ki-G35 was also modified, but the efficiency was quite low (Figure 9B and C ). However, METTL8-Iso1 was unable to introduce m 3 C modification into tRNA Leu (UUR)-G35 (Figure 9B ). These results suggested that METTL8 discriminates among some mitochondrial tRNAs via the presence or absence of G35, at least for hmtRNA Lys and hmtRNA Met . Differences in modification efficiency among various tRNAs were probably due to differences in the sequences and/or conformations of the anticodon stem, which has been proven to be an important element for m 3 C biogenesis in hmtRNA Thr . On other hand, modifications in the anticodon loop of hmtRNA Lys (5-taurinomethyl-2-thiouridine at position 34, τm 5 s 2 U34) and hmtRNA Met (5-formylcytidine at position 34, f 5 C34) ( 9 ) may also facilitate discrimination in vivo .
Several human mitochondrial tRNAs harbor the i 6 A37 modification, including hmtRNA Tyr , hmtRNA Phe and hmtRNA Trp , in addition to hmtRNA Ser (UCN) ( 9 , 21 ) (Figure 9D ). This poses the question of how METTL8-Iso1 discriminates hmtRNA Ser (UCN) from these i 6 A37-harboring tRNAs. Ec MiaA was able to modify hmtRNA Tyr , hmtRNA Phe and hmtRNA Trp albeit with variable efficiencies ( Supplementary Figure 7B ). We obtained i 6 A-hmtRNA Tyr , i 6 A-hmtRNA Phe and i 6 A-hmtRNA Trp using Ec MiaA and found that METTL8-Iso1 was indeed unable to modify i 6 A-hmtRNA Tyr and i 6 A-hmtRNA Phe (Figure 9E ). However, i 6 A-hmtRNA Trp was modified, albeit with a much lower efficiency than i 6 A-hmtRNA Ser (UCN). Among these three tRNAs, only hmtRNA Trp harbors C35 (A35 in hmtRNA Phe and U35 in hmtRNA Tyr ). These results were consistent with our earlier data showing that i 6 A-modified tRNA Ser (UCN)-G35C (with C35) could be modified by METTL8-Iso1 (Figure 8B ). Furthermore, we constructed hmtRNA Phe -G34U/A35G, hmtRNA Tyr -G34U/U35G and hmtRNA Trp -C35G mutants to mimic the anticodon loop of hmtRNA Ser (UCN) (Figure 9D ). All these mutants were efficiently i 6 A-modified by Ec MiaA compared with wild-type tRNAs ( Supplementary Figure 7B ). Indeed, METTL8-Iso1 generated even more m 3 C32 in i 6 A-hmtRNA Phe -G34U/A35G than in i 6 A-hmtRNA Ser (UCN). Likewise, the modification efficiency of i 6 A-hmtRNA Trp -C35G was significantly higher than that of i 6 A-hmtRNA Trp (Figure 9E ). Notably, hmtRNA Phe -G34U/A35G exhibited only a small increase in i 6 A modification level in comparison with wild-type hmtRNA Phe ; similarly, hmtRNA Trp -C35G displayed only a small decrease in i 6 A modification level when compared with wild-type hmtRNA Trp ( Supplementary Figure 7B ). Additionally, despite the hypomodification of i 6 A-hmtRNA Tyr , the modification of i 6 A-hmtRNA Tyr -G34U/U35G was obvious. Possibly, the significant increase in i 6 A modification of hmtRNA Tyr -G34U/U35G ( Supplementary Figure 7B ) also partially contributed to stimulated m 3 C modification (Figure 9E ). All these results clearly revealed how METTL8-Iso1 efficiently discriminates hmtRNA Ser (UCN) from other tRNAs in the presence of i 6 A37, mainly based on the tRNA anticodon loop. In vivo , m 3 C32 is absent in hmtRNA Trp ( 9 ). Our observation that i 6 A-hmtRNA Trp could be m 3 C-modified by METTL8-Iso1 in vitro suggested that other modifications in hmtRNA Trp , especially those at the anticodon loop, including τm 5 s 2 U at position 34 and/or downstream modification of i 6 A at position 37 (2-methylthio- N 6 -isopentenyladenosine, ms 2 i 6 A) ( 9 ), may prevent hmtRNA Trp from being modified by METTL8-Iso1 in vivo .
DISCUSSION
Although the types of tRNA modifications in both mammalian cytoplasmic and mitochondrial tRNAs have been remarkably expanded due to the rapid development of RNA mass spectrometry methodologies in recent years, the identification and confirmation of the corresponding tRNA-modifying enzymes has lagged behind. Indeed, genes have not yet been identified for ∼23% of the >100 human tRNA modifying enzymes that are predicted to exist ( 40 ). Among these missing genes, the mitochondrial tRNA m 3 C32 methyltransferase has long been uncertain. The identification of Mettl2 and Mettl6 as mouse tRNA m 3 C32-modifying enzymes and the exclusion of Mettl8 from tRNA modification led to the hypothesis that METTL2A, METTL2B and METTL6 in human cells are missing enzymes ( 13 , 40 ). However, the exclusive cytoplasmic localization of METTL2A/2B and METTL6 makes them unlikely to be responsible for mitochondrial tRNA modification ( 16 ). A recent study revealed that METTL8 is the missing mitochondrial m 3 C modifying enzyme ( 23 ). Here, we provide further evidence, based on mRNA and protein analyses and reconstituted activity, that an METTL8 isoform mediates hmtRNA Thr and hmtRNA Ser (UCN) m 3 C32 biogenesis.
Observations of mRNA modification ( 13 ), the involvement of METTL8 in rRNA-mediated R-loop biogenesis ( 14 ), and the presence of METTL8 in the mitochondrial proteome ( 22 ) led to confusion about the exact localization of METTL8 and its function in RNA posttranscriptional modification. We demonstrated that the METTL8 gene generates multiple protein isoforms through alternative mRNA splicing and subsequent translation. The longest isoform, METTL8-Iso1, contains a 22-amino acid MTS that targets it to the mitochondria. Other isoforms, including METTL8-Iso4, are localized to the nucleolus, consistent with results obtained by others ( 14 ). The distribution of METTL8 in the nucleolus suggests its possible role in R-loop biogenesis by modifying some yet unidentified nucleic acid constituents (Figure 10 ). It is puzzling that METTL8-Iso3, if present, differs from METTL8-Iso4 in only the very N-terminal five residues ( 1 MPRDH 5 ). Both localized in the nucleolus, but whether they exhibit similar or differential methyltransferase activity is unclear at present. Moreover, METTL8-Iso1 contains an in-frame Met residue (Met 51 ) when compared with the initiating Met of METTL8-Iso4. We cannot absolutely exclude the possibility that mRNA 1v2 (encoding METTL8-Iso1) is able to generate METTL8-Iso4 via translational re-initiation. However, fluorescence reporter assays show that ectopic expression of mRNA 1v2 in HEK293T cells drives mitochondrial localization, suggesting that this possibility, if it occurs, is low. In addition, it is worth noting that truncated METTL8 isoforms terminating in the middle of the SAM-binding site due to skipping of exon 10 were also potentially translated in human cells. The biological significance of these noncanonical METTL8 isoforms, which likely cannot catalyze m 3 C32 biogenesis due to their incomplete SAM- and tRNA-binding domain, needs to be further explored. Possibly, METTL8-Iso4 and/or the noncanonical METTL8 isoforms are involved in mRNA m 3 C modification.
Regarding the modification mechanism, METTL8-Iso1 exhibits both similarity to and divergence from both METTL2A and METTL6. For the modification of cytoplasmic tRNA Thr , METTL2A is completely reliant on the preformed t 6 A37 modification ( 16 ) catalyzed by YRDC and KEOPS in the cytoplasm ( 31 , 39 , 41 ); however, METTL8-mediated mitochondrial m 3 C32 biogenesis is independent of the formation of the t 6 A modification. On the other hand, both METTL8 and METTL2A require an anticodon loop, especially the positive determinant G35, for efficient m 3 C32 formation. Anticodon stems also contribute to m 3 C32 modification by both enzymes ( 16 ). For the modification of cytoplasmic tRNA Ser (GCU), METTL6 requires the presence of SARS1 to generate m 3 C32. SARS1 binds the long variable stem and loop region of cytoplasmic tRNA Ser (GCU). Indeed, Ue3 and the U-Ae12 base pair of tRNA Ser (GCU) are two elements in the variable stem that are critical determinants for efficient m 3 C32 modification by METTL6-SARS1 ( 16 ). However, we showed here that METTL8-Iso1 alone is able to mediate mitochondrial tRNA modification, suggesting that the activity of METTL8-Iso1 is not dependent on other helper proteins. Furthermore, METTL6 requires cytoplasmic tRNA Ser (GCU) as a scaffold to interact with SARS1; indeed, SARS2 interacts with METTL8-Iso1 but in a tRNA-independent manner, and the presence of SARS2 did not significantly stimulate METTL8-Iso1 activity. Notably, both mitochondrial tRNA Ser isoacceptors are unique due to the absence of the long variable arm, suggesting that SARS2 probably does not play a determinative role by binding to a long variable arm. This might explain why METTL8-Iso1 activity is independent of the presence of SARS2. Finally, we have proposed that the lack of the N-terminal domain of METTL6 is responsible for its reliance on the presence of SARS1 ( 16 ). METTL8-Iso1, like METTL2A, contains a long N-terminal domain compared with METTL6. The presence of this domain also likely explains why METTL8-Iso1 alone is an active m 3 C32 methyltransferase.
We also revealed an obvious divergence between the recognition of hmtRNA Thr and hmtRNA Ser (UCN) by METTL8-Iso1. METTL8-Iso1-mediated m 3 C32 biogenesis depends on i 6 A37 in hmtRNA Ser (UCN) but not its equivalent t 6 A37 in hmtRNA Thr . On the other hand, G35 plays a determinative role in hmtRNA Thr but not in hmtRNA Ser (CUN) (Figure 10 ). Based on these observations, we further determined how METTL8-Iso1 recognized only hmtRNA Thr and hmtRNA Ser (UCN) in human mitochondria. The most important discriminator seems to be G35. After the introduction of G35, both hmtRNA Met and hmtRNA Lys were found to be good substrates of METTL8-Iso1, albeit with variable modification efficiencies. On the other hand, with a determinative i 6 A37 modification, METTL8-Iso1 selected hmtRNA Ser (UCN), among other i 6 A-modified tRNAs, mainly using the anticodon loop. Indeed, when the anticodon loops of hmtRNA Phe and hmtRNA Tyr are changed, they become excellent substrates of METTL8-Iso1.
Identification of METTL8 being a mitochondrial m 3 C methyltransferase was first reported by Schöller and colleagues. They further reported that lack of m 3 C impaired mitochondrial translation and respiratory chain complex assembly and activity. In addition, increased METTL8 level was observed in pancreatic cancer ( 23 ). After submission of this study, a more recent work by Kleiber et al. also reported that METTL8 was responsible for catalyzing m 3 C32 biogenesis of hmtRNA Thr and hmtRNA Ser (UCN). They revealed the tRNA recognition and selective mechanisms of METTL8 and also found METTL8 knockout led to impaired mitochondrial translation. Both U34 and G35 were found to be recognition elements of METTL8 for hmtRNA Thr ; however, only the U34A mutant was constructed ( 42 ). Our study indeed found hmtRNA Thr -U34A was not modified by mature METTL8-Iso1; however, multiple mutations at U34 suggested that it was not a determinant in m 3 C32 modification, because hmtRNA Thr -U34C was modified with even a higher efficiency. Notably, both studies used the 407-aa METTL8 ( 23 , 42 ), exactly the METTL8-Iso1 identified in this work. However, our study investigated the splicing pattern of METTL8 mRNA in detail and observed alternative splicing modes generating several protein isoforms. Besides the METTL8-Iso1, METTL8-Iso4 was localized in nucleolus. Our study experimentally identified the MTS (Met 1 -Gln 22 ) of METTL8-Iso1, different from the predicted MTS (Met 1 -Arg 20 ) in both studies ( 23 , 42 ). In addition, our in vitro study showed that t 6 A37 modification of hmtRNA Thr only slightly stimulated m 3 C32 modification activity of mature METTL8-Iso1; however, Kleiber et al. reported that t 6 A37 increased m 3 C32 modification about 2-fold ( 42 ). It is possible that the stimulatory role of t 6 A37 is more pronounced in vivo . It is notable that all three studies demonstrated m 3 C32 modification of hmtRNA Ser (UCN) was critically reliant on i 6 A37 modification ( 23 , 42 ); however, our data revealed different recognition mechanisms of mature METTL8-Iso1 for hmtRNA Thr and hmtRNA Ser (UCN). Moreover, we found that SARS2 interacted with METTL8-Iso1 directly but did not determine m 3 C32 modification activity of the latter.
In summary, our results clearly revealed that METTL8 generated a mitochondria-localized isoform to mediate human mitochondrial tRNA m 3 C32 modification. Reconstitution of mitochondrial tRNA m 3 C32 modification activity provides valuable insights into the substrate recognition and mechanism of mitochondrial m 3 C32 biogenesis and a full understanding of both the similarities and differences between cytoplasmic and mitochondrial m 3 C32 modification by multiple m 3 C32 transferases ( 16 ). The roles of the other METTL8 isoforms would benefit from further in-depth investigation.
DATA AVAILABILITY
All data presented in this study are available within the Figures and in the Supplementary Data.
Supplementary Material
Click here for additional data file.
ACKNOWLEDGEMENTS
We thank Dr Howard Gamper (Thomas Jefferson University) for carefully reading the manuscript. We are grateful to Dr Liang Cheng (Institute of Chemistry, CAS) for providing i 6 A standard sample. We thank Dr Mo-Fang Liu in our institute for providing FBL antibody. We also thank the molecular biology core facility of our institute for technical support in UPLC – MS/MS analysis.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
FUNDING
National Key Research and Development Program of China [2017YFA0504000, 2021YFA1300800, 2021YFC2700903]; Natural Science Foundation of China [91940302, 31870811, 31822015, 81870896, 31670801, 32000889]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB19010203]; Committee of Science and Technology in Shanghai [22ZR1481300]; Shanghai Key Laboratory of Embryo Original Diseases [Shelab201904]. Funding for open access charge: Natural Science Foundation of China [31822015, 81870896, 31670801].
Conflict of interest statement . None declared
REFERENCES
1. McCown P.J. , Ruszkowska A. , Kunkler C.N. , Breger K. , Hulewicz J.P. , Wang M.C. , Springer N.A. , Brown J.A. Naturally occurring modified ribonucleosides . Wiley Interdiscip. Rev. RNA . 2020 ; 11 : e1595 . 32301288 10.1002/wrna.1595 PMC7694415
2. Suzuki T. The expanding world of tRNA modifications and their disease relevance . Nat. Rev. Mol. Cell. Biol. 2021 ; 22 : 375 – 392 . 33658722 10.1038/s41580-021-00342-0
3. El Yacoubi B. , Bailly M. , de Crecy-Lagard V. Biosynthesis and function of posttranscriptional modifications of transfer RNAs . Annu. Rev. Genet. 2012 ; 46 : 69 – 95 . 22905870 10.1146/annurev-genet-110711-155641
4. Zhou J.B. , Wang E.D. , Zhou X.L. Modifications of the human tRNA anticodon loop and their associations with genetic diseases . Cell Mol. Life Sci. 2021 ; 78 : 7087 – 7105 . 34605973 10.1007/s00018-021-03948-x PMC11071707
5. Noma A. , Yi S. , Katoh T. , Takai Y. , Suzuki T. , Suzuki T. Actin-binding protein ABP140 is a methyltransferase for 3-methylcytidine at position 32 of tRNAs in saccharomyces cerevisiae . RNA . 2011 ; 17 : 1111 – 1119 . 21518805 10.1261/rna.2653411 PMC3096043
6. D'Silva S. , Haider S.J. , Phizicky E.M. A domain of the actin binding protein abp140 is the yeast methyltransferase responsible for 3-methylcytidine modification in the tRNA anti-codon loop . RNA . 2011 ; 17 : 1100 – 1110 . 21518804 10.1261/rna.2652611 PMC3096042
7. Lentini J.M. , Alsaif H.S. , Faqeih E. , Alkuraya F.S. , Fu D DALRD3 encodes a protein mutated in epileptic encephalopathy that targets arginine tRNAs for 3-methylcytosine modification . Nat. Commun. 2020 ; 11 : 2510 . 32427860 10.1038/s41467-020-16321-6 PMC7237682
8. Suzuki T. , Suzuki T. A complete landscape of post-transcriptional modifications in mammalian mitochondrial tRNAs . Nucleic Acids Res. 2014 ; 42 : 7346 – 7357 . 24831542 10.1093/nar/gku390 PMC4066797
9. Suzuki T. , Yashiro Y. , Kikuchi I. , Ishigami Y. , Saito H. , Matsuzawa I. , Okada S. , Mito M. , Iwasaki S. , Ma D. et al . Complete chemical structures of human mitochondrial tRNAs . Nat. Commun. 2020 ; 11 : 4269 . 32859890 10.1038/s41467-020-18068-6 PMC7455718
10. Ignatova V.V. , Kaiser S. , Ho J.S.Y. , Bing X. , Stolz P. , Tan Y.X. , Lee C.L. , Gay F.P.H. , Lastres P.R. , Gerlini R. et al . METTL6 is a tRNA m 3 C methyltransferase that regulates pluripotency and tumor cell growth . Sci. Adv. 2020 ; 6 : eaaz4551 . 32923617 10.1126/sciadv.aaz4551 PMC7449687
11. Arimbasseri A.G. , Iben J. , Wei F.Y. , Rijal K. , Tomizawa K. , Hafner M. , Maraia R.J. Evolving specificity of tRNA 3-methyl-cytidine-32 (m 3 C32) modification: a subset of tRNAs Ser requires N 6 -isopentenylation of A37 . RNA . 2016 ; 22 : 1400 – 1410 . 27354703 10.1261/rna.056259.116 PMC4986895
12. Han L. , Marcus E. , D'Silva S. , Phizicky E.M S. cerevisiae trm140 has two recognition modes for 3-methylcytidine modification of the anticodon loop of tRNA substrates . RNA . 2017 ; 23 : 406 – 419 . 28003514 10.1261/rna.059667.116 PMC5311504
13. Xu L. , Liu X. , Sheng N. , Oo K.S. , Liang J. , Chionh Y.H. , Xu J. , Ye F. , Gao Y.G. , Dedon P.C. et al . Three distinct 3-methylcytidine (m 3 C) methyltransferases modify tRNA and mRNA in mice and humans . J. Biol. Chem. 2017 ; 292 : 14695 – 14703 . 28655767 10.1074/jbc.M117.798298 PMC5582859
14. Zhang L.H. , Zhang X.Y. , Hu T. , Chen X.Y. , Li J.J. , Raida M. , Sun N. , Luo Y. , Gao X. The SUMOylated METTL8 induces R-loop and tumorigenesis via m 3 c . iScience . 2020 ; 23 : 100968 . 32199293 10.1016/j.isci.2020.100968 PMC7082549
15. Cui J. , Liu Q. , Sendinc E. , Shi Y. , Gregory R.I. Nucleotide resolution profiling of m 3 C RNA modification by HAC-seq . Nucleic Acids Res . 2021 ; 49 : e27 . 33313824 10.1093/nar/gkaa1186 PMC7969016
16. Mao X.L. , Li Z.H. , Huang M.H. , Wang J.T. , Zhou J.B. , Li Q.R. , Xu H. , Wang X.J. , Zhou X.L. Mutually exclusive substrate selection strategy by human m 3 C RNA transferases METTL2A and METTL6 . Nucleic Acids Res. 2021 ; 49 : 8309 – 8323 . 34268557 10.1093/nar/gkab603 PMC8373065
17. Chen R. , Zhou J. , Liu L. , Mao X.L. , Zhou X. , Xie W. Crystal structure of human METTL6, the m 3 C methyltransferase . Commun. Biol. 2021 ; 4 : 1361 . 34862464 10.1038/s42003-021-02890-9 PMC8642396
18. Lin H. , Miyauchi K. , Harada T. , Okita R. , Takeshita E. , Komaki H. , Fujioka K. , Yagasaki H. , Goto Y.I. , Yanaka K. et al . CO 2 -sensitive tRNA modification associated with human mitochondrial disease . Nat. Commun. 2018 ; 9 : 1875 . 29760464 10.1038/s41467-018-04250-4 PMC5951830
19. Zhou J.B. , Wang Y. , Zeng Q.Y. , Meng S.X. , Wang E.D. , Zhou X.L. Molecular basis for t 6 A modification in human mitochondria . Nucleic Acids Res. 2020 ; 48 : 3181 – 3194 . 32047918 10.1093/nar/gkaa093 PMC7102964
20. Golovko A. , Hjalm G. , Sitbon F. , Nicander B. Cloning of a human tRNA isopentenyl transferase . Gene . 2000 ; 258 : 85 – 93 . 11111046 10.1016/s0378-1119(00)00421-2
21. Lamichhane T.N. , Mattijssen S. , Maraia R.J. Human cells have a limited set of tRNA anticodon loop substrates of the tRNA isopentenyltransferase TRIT1 tumor suppressor . Mol. Cell Biol. 2013 ; 33 : 4900 – 4908 . 24126054 10.1128/MCB.01041-13 PMC3889556
22. Rath S. , Sharma R. , Gupta R. , Ast T. , Chan C. , Durham T.J. , Goodman R.P. , Grabarek Z. , Haas M.E. , Hung W.H.W. et al . MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations . Nucleic Acids Res. 2021 ; 49 : D1541 – D1547 . 33174596 10.1093/nar/gkaa1011 PMC7778944
23. Scholler E. , Marks J. , Marchand V. , Bruckmann A. , Powell C.A. , Reichold M. , Mutti C.D. , Dettmer K. , Feederle R. , Huttelmaier S. et al . Balancing of mitochondrial translation through METTL8-mediated m 3 C modification of mitochondrial tRNAs . Mol. Cell . 2021 ; 81 : 4810 – 4825 . 34774131 10.1016/j.molcel.2021.10.018 PMC11214777
24. Wang Y. , Zeng Q.Y. , Zheng W.Q. , Ji Q.Q. , Zhou X.L. , Wang E.D. A natural non-Watson-Crick base pair in human mitochondrial tRNA Thr causes structural and functional susceptibility to local mutations . Nucleic Acids Res. 2018 ; 46 : 4662 – 4676 . 29648639 10.1093/nar/gky243 PMC5961198
25. Collinet B. , Friberg A. , Brooks M.A. , van den Elzen T. , Henriot V. , Dziembowski A. , Graille M. , Durand D. , Leulliot N. , Saint Andre C. et al . Strategies for the structural analysis of multi-protein complexes: lessons from the 3D-Repertoire project . J. Struct. Biol. 2011 ; 175 : 147 – 158 . 21463689 10.1016/j.jsb.2011.03.018
26. Wang Y. , Zhou J.B. , Zeng Q.Y. , Wu S.Q. , Xue M.Q. , Fang P.F. , Wang E.D. , Zhou X.L. Hearing impairment-associated KARS mutations lead to defects in aminoacylation of both cytoplasmic and mitochondrial tRNA Lys . Sci. China Life Sci. 2020 ; 63 : 1227 – 1239 . 32189241 10.1007/s11427-019-1619-x
27. Fechter P. , Rudinger J. , Giege R. , Theobald-Dietrich A. Ribozyme processed tRNA transcripts with unfriendly internal promoter for T7 RNA polymerase: production and activity . FEBS Lett. 1998 ; 436 : 99 – 103 . 9771901 10.1016/s0014-5793(98)01096-5
28. Sissler M. , Helm M. , Frugier M. , Giege R. , Florentz C. Aminoacylation properties of pathology-related human mitochondrial tRNA(Lys) variants . RNA . 2004 ; 10 : 841 – 853 . 15100439 10.1261/rna.5267604 PMC1370574
29. Zeng Q.Y. , Peng G.X. , Li G. , Zhou J.B. , Zheng W.Q. , Xue M.Q. , Wang E.D. , Zhou X.L. The G3-U70-independent tRNA recognition by human mitochondrial alanyl-tRNA synthetase . Nucleic Acids Res. 2019 ; 47 : 3072 – 3085 . 30952159 10.1093/nar/gkz078 PMC6451123
30. El Yacoubi B. , Lyons B. , Cruz Y. , Reddy R. , Nordin B. , Agnelli F. , Williamson J.R. , Schimmel P. , Swairjo M.A. , de Crecy-Lagard V. The universal yrdc/Sua5 family is required for the formation of threonylcarbamoyladenosine in tRNA . Nucleic Acids Res. 2009 ; 37 : 2894 – 2909 . 19287007 10.1093/nar/gkp152 PMC2685093
31. El Yacoubi B. , Hatin I. , Deutsch C. , Kahveci T. , Rousset J.P. , Iwata-Reuyl D. , Murzin A.G. , de Crecy-Lagard V. A role for the universal Kae1/Qri7/YgjD (COG0533) family in tRNA modification . EMBO J. 2011 ; 30 : 882 – 893 . 21285948 10.1038/emboj.2010.363 PMC3049207
32. Soderberg T. , Poulter C.D. Escherichia coli dimethylallyl diphosphate:tRNA dimethylallyltransferase: essential elements for recognition of tRNA substrates within the anticodon stem-loop . Biochemistry . 2000 ; 39 : 6546 – 6553 . 10828971 10.1021/bi992775u
33. Zhou X.L. , Chen Y. , Zeng Q.Y. , Ruan Z.R. , Fang P. , Wang E.D. Newly acquired N-terminal extension targets threonyl-tRNA synthetase-like protein into the multiple tRNA synthetase complex . Nucleic Acids Res. 2019 ; 47 : 8662 – 8674 . 31287872 10.1093/nar/gkz588 PMC6794377
34. Claros M.G. , Vincens P. Computational method to predict mitochondrially imported proteins and their targeting sequences . Eur. J. Biochem. 1996 ; 241 : 779 – 786 . 8944766 10.1111/j.1432-1033.1996.00779.x
35. Yao Y.N. , Wang L. , Wu X.F. , Wang E.D. The processing of human mitochondrial leucyl-tRNA synthetase in the insect cells . FEBS Lett. 2003 ; 534 : 139 – 142 . 12527375 10.1016/s0014-5793(02)03833-4
36. Wang Y. , Zhou X.L. , Ruan Z.R. , Liu R.J. , Eriani G. , Wang E.D. A human disease-causing point mutation in mitochondrial threonyl-tRNA synthetase induces both structural and functional defects . J. Biol. Chem. 2016 ; 291 : 6507 – 6520 . 26811336 10.1074/jbc.M115.700849 PMC4813579
37. Carapito C. , Kuhn L. , Karim L. , Rompais M. , Rabilloud T. , Schwenzer H. , Sissler M. Two proteomic methodologies for defining N-termini of mature human mitochondrial aminoacyl-tRNA synthetases . Methods . 2017 ; 113 : 111 – 119 . 27793688 10.1016/j.ymeth.2016.10.012
38. Peng G.X. , Zhang Y. , Wang Q.Q. , Li Q.R. , Xu H. , Wang E.D. , Zhou X.L. The human tRNA taurine modification enzyme GTPBP3 is an active GTPase linked to mitochondrial diseases . Nucleic Acids Res. 2021 ; 49 : 2816 – 2834 . 33619562 10.1093/nar/gkab104 PMC7969015
39. Wang J.T. , Zhou J.B. , Mao X.L. , Zhou L. , Chen M. , Zhang W. , Wang E.D. , Zhou X.L. Commonality and diversity in tRNA substrate recognition in t 6 A biogenesis by eukaryotic KEOPSs . Nucleic Acids Res. 2022 ; 50 : 2223 – 2239 . 35104889 10.1093/nar/gkac056 PMC8887486
40. de Crecy-Lagard V. , Boccaletto P. , Mangleburg C.G. , Sharma P. , Lowe T.M. , Leidel S.A. , Bujnicki J.M. Matching tRNA modifications in humans to their known and predicted enzymes . Nucleic Acids Res. 2019 ; 47 : 2143 – 2159 . 30698754 10.1093/nar/gkz011 PMC6412123
41. Srinivasan M. , Mehta P. , Yu Y. , Prugar E. , Koonin E.V. , Karzai A.W. , Sternglanz R. The highly conserved KEOPS/EKC complex is essential for a universal tRNA modification, t 6 A . EMBO J. 2011 ; 30 : 873 – 881 . 21183954 10.1038/emboj.2010.343 PMC3049205
42. Kleiber N. , Lemus-Diaz N. , Stiller C. , Heinrichs M. , Mai M.M. , Hackert P. , Richter-Dennerlein R. , Hobartner C. , Bohnsack K.E. , Bohnsack M.T. The RNA methyltransferase METTL8 installs m 3 C32 in mitochondrial tRNAs(Thr/Ser(UCN)) to optimise tRNA structure and mitochondrial translation . Nat. Commun. 2022 ; 13 : 209 . 35017528 10.1038/s41467-021-27905-1 PMC8752778